Biosimilar manufacturers have been given $5 million by the federal government for campaigns to encourage clinicians to prescribe cheaper versions of agents such as infliximab. A $5 million federal government grant under the Biosimilar Awareness Initiative has been awarded to a new educational arm of the Generic and Biosimilar Medicines Association (GBMA). The funding assigned ...
Expect more biosimilar education from industry group
3 May 2018